.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
Farmers Insurance
AstraZeneca
Julphar
Covington
Mallinckrodt
Fuji
Teva
Accenture
Cantor Fitzgerald

Generated: September 19, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Summary for Patent: ► Subscribe

Title:Treatment of ophthalmic conditions
Abstract: Ophthalmic conditions such as presbyopia, myopia, and astigmatism can be corrected by the use of a molding contact lens in combination with a pharmaceutical composition suitable for delivery to the eye. The molding contact lenses are preferably commercially available and are not specifically designed for orthokeratology. The agents in the pharmaceutical compositions such as hyaluronase allow the cornea of the eye to be molded in order to correct the refractive error of the eye. The contact lenses and the pharmaceutical composition induce a change in the radius of curvature of the anterior surface of the cornea, thereby correcting the refractive error of the eye. One advantage of the inventive technique is that the patient with his or her own individual visual needs guides the treatment until the patient near and far visual needs are met. The present invention also provides for kits, which contain molding contact lenses, pharmaceutical composition suitable for delivery to the eye, and instructions, useful in the inventive system.
Inventor(s): Osio Sancho; Alberto (Mexico, D.F., MX)
Assignee: Osio Corporation (Coronado, CA)
Application Number:15/004,246
Patent Claims:1. A non-invasive method for treating an ophthalmic condition associated with an error in refraction of the eye, the method comprising steps of: providing a contact lens; providing eye drops comprising an effective amount of hyaluronidase and collagenase, wherein the collagenase is not matrix metalloproteinase 1 or matrix metalloproteinase 2; applying the contact lens to an eye of a patient suffering from the ophthalmic condition; and applying the eye drops to the eye of the patient; wherein the treatment corrects the patient's vision, and the treatment results in corrected vision for at least 6 months.

2. The method of claim 1, wherein the contact lens is an extended wear contact lens.

3. The method of claim 1, wherein the contact lens is a gas permeable contact lens.

4. The method of claim 1, wherein the contact lens is a molding contact lens.

5. The method of claim 1, wherein the treatment induces a change in the shape of the cornea.

6. The method of claim 1, wherein the treatment induces a change in the physiology and anatomy of the cornea by changing the radius of curvature of the anterior surface of the eye.

7. The method of claim 1, wherein the eye drops further comprise at least one agent selected from the group consisting of enzymes, anesthetics, vitamins, zinc, antibiotics, anti-allergic agents, carbamide, cytokinases, vasoconstrictors, anti-viral agents, anti-fungal agents, anti-inflammatory agents, and lubricants.

8. The method of claim 1, wherein the eye drops further comprise a polymer.

9. The method of claim 8, wherein the polymer is selected from the group consisting of methylcellulose, cellulose, polyvinyl alcohol, and polyethylene glycol.

10. The method of claim 1, wherein the eye drops are hypertonic.

11. The method of claim 1, wherein the eye drops are hypotonic.

12. The method of claim 1, wherein the eye drops comprise about 0.01% to about 10% (weight percent) hyaluronidase, and about 0.01% to about 10% (weight percent) collagenase.

13. The method of claim 1, wherein the treatment results in the correction of up to 3 diopters of refractive error without surgery.

14. The method of claim 1, wherein the treatment results in the correction of up to 4 diopters of refractive error without surgery.

15. The method of claim 1, wherein the treatment results in the correction of up to 5 diopters of refractive error without surgery.

16. The method of claim 1, whereby the treatment results in corrected vision for at least 1 year.

17. The method of claim 1, wherein the ophthalmic condition is a residual refractive error present after a surgical procedure involving the eye.

18. The method of claim 17, wherein the surgical procedure is keratotomy, keratomileusis by a freezing process, automated lamellar keratomileusis, photo-reactive keratomileusis, laser-assisted in situ keratomileusis, later intrastromal keratomileusis, laser epithelial keratomileusis, conductive keratoplasty, or scleral resection.

19. The method of claim 17, wherein the surgical procedure includes cutting corneal or sclera tissue and/or ablating areas of the cornea.

20. The method of claim 1, wherein the ophthalmic condition is a genetic refractive defect.

Summary for Patent: ► Subscribe

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Mexico011987Dec 19, 2003

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Inventors Patent Expiration Status Orphan Source
Advance Biofactures
SANTYL
collagenase
VIAL1019950011965-06-04► Subscribe Osio Corporation (Coronado, CA) Osio Sancho; Alberto (Mexico, D.F., MX) ► SubscribeRXsearch
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Publication Date
Australia2004308326Feb 10, 2011
Australia2004308326Jul 14, 2005
BrazilPI0417785Mar 20, 2007
Canada2549333Aug 05, 2014
Canada2549333Jul 14, 2005
China100591354Feb 24, 2010
China1901882Jan 24, 2007
Costa Rica8453Dec 07, 2006
EcuadorSP066657Nov 24, 2006
Egypt24420May 25, 2009
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.


« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Harvard Business School
Fuji
Boehringer Ingelheim
Chubb
Covington
Dow
Farmers Insurance
Johnson and Johnson
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot